China Deals looks at the level of Merger and acquisition activity between Chinese and European companies.
Market update on European non-core loan portfolio transactions in 2012 and outlook for 2013
If you are considering merging with or acquiring businesses in the UK, PwC has a deals team dedicated to provide Chinese clients a full-suite, ‘one-stop shop’ service, assisting you at each stage during the transaction process.
Global economic uncertainty and a drop in commodity prices has led to marked slowdown in merger and acquisitions (M&A) in 2012, despite the blockbuster start with a Glencore/Xstrata transaction, according to PwC’s new Mining Deals report launched today.
Overview of Pharmaceutical mergers and acquisitions activity 2012, Quarter two.
With our latest analysis of Pharmaceutical (Pharma) merger and acquisition (M&A) deals our specialists, Michelle Ritchie, Steve Aherne, Lucy Stapleton, Andrew McKechnie and Jo Pisani talk about what current trends and future opportunities we are seeing in the market. Our analysis is based on the deal tracking done by Dealogic and we have found that Pharma is not immune to the economic downturn, and this has clearly impacted the number of deals that have happened this year.
A review of sector trends and the deal market.
This publication explains why Government and public sector organisations world-wide must adjust to the new reality of ‘doing more for less’ (or ‘doing less for less’) and focus on the outcomes society needs and wants.
In our 4th annual European outlook we explore the activity and outlook for the key European non core asset markets.
This edition of the our Valuation Index focuses on listed property company shares, looking in particular at pricing compared to the underlying commercial property values.